Antibody Oxidation’s Hidden Handedness Comes Into View
Integrated NMR and LC-MS analysis distinguishes elusive stereochemical forms of methionine oxidation in IgG1 Fc regions, offering a sharper tool for biologic drug quality control
Clinical Scorecard: Antibody Oxidation’s Hidden Handedness Comes Into View
At a Glance
Category Detail
Condition Antibody oxidation in therapeutic antibodies Key Mechanisms Methionine oxidation affecting antibody stability and receptor interactions Target Population Patients receiving antibody therapeutics Care Setting Pharmaceutical manufacturing and quality control
Key Highlights
New analytical strategy reveals stereoisomers of methionine sulfoxide in antibodies Focus on Met252 and Met428 in IgG1 antibodies Oxidation alters receptor binding and stability NMR and LC-MS techniques provide atomic resolution insights Enhanced stability testing and manufacturing control for antibody drugs Guideline-Based Recommendations
Diagnosis
Utilize NMR spectroscopy and LC-MS for detailed analysis of antibody oxidation Management
Implement selective enzymatic reduction to assess stereochemical diversity Monitoring & Follow-up
Regularly evaluate oxidation levels of methionine residues in therapeutic antibodies Risks
Potential alterations in receptor binding and in vivo persistence due to oxidation Patient & Prescribing Data
Individuals receiving monoclonal antibody therapies
Understanding methionine oxidation can improve therapeutic efficacy and safety
Clinical Best Practices
Incorporate advanced analytical techniques in antibody drug development Monitor oxidation states to ensure therapeutic stability Enhance manufacturing controls based on oxidation profiles References
